Global ADC Drug CDMO Service Market Growth (Status and Outlook) 2024-2030

Global ADC Drug CDMO Service Market Growth (Status and Outlook) 2024-2030

ADC drugs, also known as antibody drug coupling agents, work by coupling small molecule drugs with antibodies through linkers to form drugs. These drugs combine the high targeting ability of antibodies with the strong killing power of chemical drugs, and are considered the most promising next-generation antibody technology. To reduce research and development costs, most ADC drug development worldwide chooses outsourcing, leveraging CDMO companies to enter clinical and market more quickly. CDMO services refer to pharmaceutical and biotechnology companies outsourcing the research and production of their drugs or biological products to professional CDMO companies. These CDMO companies provide a range of services, including but not limited to drug synthesis, chemical and biological analysis, formulation development, clinical production, and commercial production. The core of CDMO services lies in its ability to customize and specialize, which can meet the specific needs of different customers at different stages.

The global ADC Drug CDMO Service market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “ADC Drug CDMO Service Industry Forecast” looks at past sales and reviews total world ADC Drug CDMO Service sales in 2022, providing a comprehensive analysis by region and market sector of projected ADC Drug CDMO Service sales for 2023 through 2029. With ADC Drug CDMO Service sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world ADC Drug CDMO Service industry.

This Insight Report provides a comprehensive analysis of the global ADC Drug CDMO Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on ADC Drug CDMO Service portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global ADC Drug CDMO Service market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for ADC Drug CDMO Service and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global ADC Drug CDMO Service.

United States market for ADC Drug CDMO Service is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for ADC Drug CDMO Service is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for ADC Drug CDMO Service is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key ADC Drug CDMO Service players cover WuXi XDC, Lonza, Merck, Axplora, Catalent, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of ADC Drug CDMO Service market by product type, application, key players and key regions and countries.

Segmentation by Type:
Antibody
Linker and Payload
Other

Segmentation by Application:
Small and Medium-sized Pharmaceutical Companies
Large Pharmaceutical Companies

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Antibody
Linker and Payload
Other

Segmentation by Application:
Small and Medium-sized Pharmaceutical Companies
Large Pharmaceutical Companies

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
WuXi XDC
Lonza
Merck
Axplora
Catalent
Abbvie
MabPlex International
TOT Biopharm
Zencore Biologics
Healsun Biopharm

Please note: The report will take approximately 2 business days to prepare and deliver.